Stay updated on Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a minor site update with no changes to the study information displayed.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedA site revision tag v3.4.2 was added and a government funding status notice (and an earlier revision note) was removed; there are no changes to the study data or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check36 days agoChange DetectedA site-wide notice about government funding lapse and NIH Clinical Center status was added, along with a version update (Revision: v3.4.1).SummaryDifference0.5%

- Check43 days agoChange DetectedAdded a glossary toggle and minor wording/capitalization updates to QC labels and the revision text. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check57 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 on the page.SummaryDifference0.1%

- Check79 days agoChange DetectedLocation information on the study page was updated to include a standalone 'Locations' section with Louisiana, replacing the former 'Louisiana Locations' label. The 'HHS Vulnerability Disclosure' link was removed from the page footer.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.